Literature DB >> 3998064

Protein binding of endogenous digoxin-immunoactive factors in human serum and its variation with clinical condition.

R Valdes, S W Graves.   

Abstract

We previously identified endogenous digoxin-like immunoactivity in serum from pregnant women, newborn infants, and patients in renal failure. This activity is due to an endogenous factor(s) that cross-reacts with antibodies raised against digoxin. Using serum from the above sources as well as serum and urine from normal individuals, we further characterized these immunoreactive factors. The factors are water soluble, heat stable, and neutral in molecular charge. That isolated from serum has an apparent mol wt of 200 daltons, as estimated by membrane partitioning. The factor from urine has twice this apparent mol wt, an apparent higher affinity for the digoxin antisera, and is less resistant to acid hydrolysis. It may represent a conjugated metabolite of the factor from serum. The immunoactive factor in serum is noncovalently bound to serum protein, and we describe methods for estimating total, weakly protein-bound (i.e. heat-dissociable), tightly protein-bound (i.e. not heat-dissociable), and unbound (free) activity. Levels measured directly in serum by RIA represent the unbound and weakly protein-bound serum components. In normal subjects, over 90% of the total endogenous immunoactivity in serum is tightly but reversibly bound to protein and not detectable by direct measurement with conventional RIAs. Concentrations determined by direct measurement in serum from patients with renal failure [128 +/- 38 pg digoxin equivalents/ml (mean +/- SE)], pregnant women (141 +/- 12), and neonates (230 +/- 7) consistently exceeded those in normal subjects (61 +/- 3). Chromatography and ultrafiltration studies suggest that these differences are due to increased amounts of weakly protein-bound factor in these subjects rather than to a greater amount of total immunoactive factor. Altered protein binding of this endogenous factor seems to play a predominant role in the detection of digoxin-like immunoactivity in human serum. Our data also suggest that carrier proteins may play a prominent role in the transport of this endogenous immunoactive factor in blood.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3998064     DOI: 10.1210/jcem-60-6-1135

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Sodium transport inhibitors in pregnancy-induced hypertension.

Authors:  L Poston
Journal:  Cardiovasc Drugs Ther       Date:  1990-03       Impact factor: 3.727

2.  Endogenous digoxin-like immunoreactivity in congestive heart failure.

Authors:  L Shilo; A Adawi; G Solomon; L Shenkman
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-15

3.  Total digoxin-like immunoreactive factor(s) in healthy population, uncomplicated term pregnancies and neonates.

Authors:  N Krivoy; P Jakobi; E Paldi; G Alroy
Journal:  J Endocrinol Invest       Date:  1990-01       Impact factor: 4.256

4.  Modifications induced by plasma of gestational hypertensive women on the Na+/K+-ATPase obtained from human placenta.

Authors:  N Cester; R A Rabini; A L Tranquilli; G Lucarelli; E Salvolini; R Staffolani; E Amler; G Zolese; L Mazzanti
Journal:  Mol Cell Biochem       Date:  1997-05       Impact factor: 3.396

5.  Pregnane glycosides interfere with steroidogenic enzymes to down-regulate corticosteroid production in human adrenocortical H295R cells.

Authors:  Slavko Komarnytsky; Debora Esposito; Alexander Poulev; Ilya Raskin
Journal:  J Cell Physiol       Date:  2013-05       Impact factor: 6.384

6.  A New Animal Model to Study Endogenous Cardiotonic Steroids and the Progression of Cardiovascular Events in Salt-Sensitive Hypertension.

Authors:  Estela S Estape; Ivette Torres-Negron; Lorena Gonzalez; Manuel Martinez-Maldonado
Journal:  Int Arch Transl Med       Date:  2015-05-30

7.  Insulin resistance and endogenous digoxin-like factor in obese hypertensive patients with glucose intolerance.

Authors:  G Andronico; G Mulé; M T Mangano; G Piazza; M Donatelli; G Cerasola; G D Bompiani
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

8.  Low to Normal Plasma Levels of Marinobufagenin 24 Hours or More after an Ischemic Stroke: A Pilot Study.

Authors:  Estela S Estapé; Lorena González-Sepúlveda; Wen Wei; Ingrid Rodríguez-Rivera; Ivette Torres-Negrón
Journal:  Int Arch Transl Med       Date:  2018-09-06

9.  Inhibition of endogenous ouabain by atrial natriuretic peptide is a guanylyl cyclase independent effect.

Authors:  Gulay Tegin; Yonglin Gao; John M Hamlyn; Barbara J Clark; Rif S El-Mallakh
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.